SentreHEART Headquarters

Founded in 2005, SentreHEART is focused on remote suture delivery for immediate and complete closure of anatomic structures. For decades, clinicians have been using suture for anatomic closure, but due to technique and operator variability, the results are frequently sub-optimal. The LARIAT Suture Delivery Device enables clinicians to precisely deliver a pre-tied suture loop to the ideal location for closure and reduces the likelihood of leaks or gaps due to operator variability.

SentreHEART is committed to clinical evidence development and is currently sponsoring the FDA-approved prospective, multi-center, randomized controlled trial known as the aMAZE Trial. This trial is designed to demonstrate the additive benefits of LARIAT LAA closure combined with pulmonary vein isolation as a means of improving outcomes in patients with persistent or longstanding persistent atrial fibrillation.